Skip to content
Tablet Allopathic

Hapytab 50 mg tablet

Generic: Desvenlafaxine Succinate

Company: Eskayef Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength50 mg
PackStrip: 100.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated August 30, 2025.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Desvenlafaxine Succinate 50 mg tablets

Prices as listed on BestinMeds.

2 brands listed
Hapytab (this medicine)10.00 taka per tablet
Nevola10.00 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Desvenlafaxine Succinate guide

Indications

Desvenlafaxine Succinate is indicated for the treatment of Major Depressive Disorder (MDD). It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Patients should be periodically reassessed to determine the need for continued treatment.

Dosage and administration

The recommended dose for Desvenlafaxine Succinate is 50 mg once daily, with or without food. In clinical studies, doses of 50-400 mg/day were shown to be effective. When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimize discontinuation symptoms. Desvenlafaxine Succinate should be taken at approximately the same time each day. Tablets must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.

Side effects

Nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, dry mouth and specific male sexual function disorders.

Precautions and warnings

Patients with Major Depressive Disorder (MDD) both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether they are taking antidepressant medications or not and this risk may persist until significant remission occurs. Pooled analysis of short-term placebo-controlled studies of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents and young adults (aged 18 to 24) with Major Depressive Disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24.

Pregnancy and lactation

Pregnancy Category C. Desvenlafaxine should be used during pregnancy only if the potential benefits justify the potential risks to the fetus. Desvenlafaxine (O-desmethylvenlafaxine) is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from Desvenlafaxine a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250